kras

KRAS G12C inhibitor 16 is a potent inhibitor of KRAS G12C.

KRAS inhibitor-4 developed as anticancer agents, is a potent KRAS inhibitor.

KRAS inhibitor-10 (WO2021005165 A1, compound 11) is a potent and selective inhibitor of RAS proteins, with a specific focus on KRAS proteins. This orally active anti-cancer agent demonstrates strong efficacy in cancer research, specifically in pancreatic cancer, breast cancer, multiple myeloma, leukemia, and lung cancer. KRAS inhibitor-10 is classified as a tetrahydroisoquinoline compound. Its inhibitory properties provide valuable insights and potential therapeutic applications in the field of oncology [1].

KRAS G13D peptide, a 25-mer sequence, is derived from the KRAS activating oncogene mutation and serves as an immune potentiator. This peptide possesses immunogenic properties and can be utilized for the development of a KRAS vaccine.

KRAS G12D inhibitor 5 is a potential treatment for pancreatic cancer that targets the KRAS G12D mutation.

KRAS mutant protein inhibitor 1 is a KRAS mutant protein inhibitor [for potential treatment in cancer].

KRAS G12D inhibitor 6 is an efficacious compound that effectively inhibits KRAS G12D.

KRAS G12D inhibitor 7, is a highly potent inhibitor specifically targeting KRAS G12D.

KRAS G12C inhibitor 18 is a potent and orally active compound that inhibits KRAS G12C, demonstrating significant anti-tumor activities.

KRAS G12C inhibitor 19 is a potent KRAS G12C inhibitor that demonstrates anti-tumor activity in cellular assays and inhibits tumor growth [1].

KRAS G12D inhibitor 14 is a potent compound that binds the KRAS G12D protein (Kd: 33 nM) and selectively inhibits the active form KRAS G12D-GTP, but not KRAS G13D.

KRAS G12D mutation regulator 4 can be used in studies about Ras.

KRAS G12C mutant protein inhibitor A-1 can be used in studies about Ras.

KRAS inhibitor FB9 can be used in studies about Ras.

Kras binder 12 can be used in studies about Ras.

Kras4B G12D-IN-1 is an anticancer agent that functions as an inhibitor of the Kras4B G12D protein. It effectively reduces the expression of Kras protein in mouse embryonic fibroblasts (MEFs) harboring the Kras4B G12D mutation[1].

KRAS inhibitor-9 (DUN09716) is a potent KRAS inhibitor with Kd of 92 μM that blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSC-LC cells with KRAS mutation but not normal lung cells

3344 is an inhibitor of KRAS-effector interactions,with an affnity of 126nm.

KRAS G12D inhibitor 1 (example 243) is an inhibitor of KRAS G12D, exhibiting an IC50 of 0.8 nM for KRAS G12D-mediated ERK phosphorylation [1].

KRas G12C inhibitor 1 is a compound that selectively inhibits the KRas G12C protein.

KRAS G12C Inhibitor 13 is a specific inhibitor targeting the KRAS G12C mutation.

KRAS G12C inhibitor 14 is a potent compound with an IC50 of 18 nM [1].

KRAS G12C inhibitor 15 is a potent inhibitor of the KRAS G12C protein.

KRAS G12C inhibitor 17 is a potent inhibitor of the KRAS G12C protein.